Pharmacokinetics and Treatment Strategies in Metastatic Colorectal Cancer

The pharmacokinetics of agents used in metastatic colorectal cancer encompass absorption, distribution, metabolism and elimination processes that determine systemic exposure and tumour penetration. Small-molecule cytotoxics such as fluoropyrimidines and platinum compounds exhibit relatively predictable linear kinetics, whereas monoclonal antibodies like bevacizumab and cetuximab display nonlinear, target-mediated drug disposition owing to high-affinity binding to vascular endothelial growth factor A (VEGF-A) or epidermal growth factor receptor (EGFR). Inter-individual variability in clearance and volume of distribution is influenced by body weight, serum protein levels, organ function and genetic polymorphisms within angiogenesis-related pathways. Optimising dosing through population pharmacokinetic models, therapeutic drug monitoring and pharmacogenomic stratification has enabled more precise exposure-response relationships. Treatment strategies integrate cytotoxic backbones—FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) and FOLFIRI (5-fluorouracil, leucovorin, irinotecan)—with targeted agents to inhibit angiogenesis (bevacizumab, aflibercept) or EGFR signalling (cetuximab, panitumumab). First-line regimens are selected on RAS and BRAF mutational status, tumour sidedness and patient comorbidities. Subsequent lines involve switching cytotoxics or introducing alternative antiangiogenic monoclonals. Dose escalations and interval modifications guided by trough levels and model simulations aim to overcome primary resistance and mitigate toxicity. Innovative imaging biomarkers have sought to visualise antibody distribution in vivo to tailor individualised dosing. Across all approaches, balancing efficacy with quality of life remains paramount, with ongoing efforts to translate pharmacokinetic insights into global practice guidelines.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacokinetics and Treatment Strategies in Metastatic Colorectal Cancer publication trend

The graph below shows the total number of articles in pharmacokinetics and treatment strategies in metastatic colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Pharmacokinetics: Study of drug movement through the body, including absorption, distribution, metabolism and excretion.

Target-mediated drug disposition (TMDD): Nonlinear pharmacokinetic behaviour resulting from high-affinity binding of a drug to its pharmacological target.

Therapeutic drug monitoring (TDM): Measurement of drug concentrations in biological fluids to individualise dosing and optimise therapeutic effect.

Monoclonal antibody: Laboratory-engineered protein designed to bind specifically to a molecular target such as VEGF or EGFR.

Progression-free survival (PFS): Time during and after treatment in which a patient’s cancer does not worsen.

References

1. [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging (2019).
2. Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review. Journal of Personalized Medicine (2020).
3. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. International Journal of Molecular Sciences (2020).